Zimbabwe has turned down a substantial American health deal valued at $367m (£272m) spanning five years over Washington's insistence on confidential information.
This rejection came to light following a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
An official spokesperson has since explained that the US was requesting biological samples for scientific study and commercial purposes but was unwilling to share the benefits from future vaccines.
"We are forced to start the difficult and regrettable task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for further talks to secure a agreement agreeable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Background
This development comes after a comparable situation in Kenya, where a court suspended a similar health funding agreement after concerns were raised about the safety of citizens' health data.
After resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government agreements to boost openness and responsibility.
Based on statements, Sixteen African countries have to date signed similar health pacts, representing over $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no corresponding assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our nation would provide the raw materials for medical research without any assurance that the end products would be available to our citizens if a new health crisis arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its pursuit of bilateral deals were upending structures already set up through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This system is intended to ensure that when a country provides its data, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
The government's concerns over the US deal "are not meant as hostility towards the US," he added.
"We encourage continued dialogue with our US partners on how subsequent co-operation could be designed in a manner that respects the sovereignty and interests of both nations."
Health Experts Response
A leading public health body stated it acknowledged the official position, but suggested that negotiations must proceed given that a large portion of the nation's Aids initiatives depended on external financing.
"If specific concerns arise, including those involving information security or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," the group added.
This impasse underscores the continuing tensions between accepting crucial international aid and safeguarding local interests in an ever more data-driven world.